CVRdatabase
Menu

Orifarm Manufacturing Hobro A/S

Public limited companyCVR 41059044HobroActive

Orifarm Manufacturing Hobro A/S is a public limited company, based in Hobro, active in manufacture of pharmaceutical preparations, founded in 2020. Net profit rose 31% from 2024 to 2025, ending at DKK 3.8m. With 64 employees, the company is about 6 times larger than the industry median. Gross profit is higher than that of 79% of the companies in the industry in the database.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profitDKK 57m−2.7% vs. 2024
Net profitDKK 3.8m+31.4% vs. 2024
EquityDKK 46m−5.8% vs. 2024
Employees64latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit fell 3% (2024 → 2025), to DKK 57m.
  • Net profit rose 31% (2024 → 2025), to DKK 3.8m.
  • Equity fell 6% (2024 → 2025), to DKK 46m.

Employees

  • 3 more employees than a year earlier: 64 (07/2026) against 61 (07/2025).

Management and owners, last 24 months

  • New in management: Hans Carl Bøgh-Sørensen (chair of the board, 17/03/2025), Nicki Lund Kristensen (board member, 20/10/2025) and Mads Fink Eriksen (ceo, 16/04/2026) (+1).
  • Stepped down: Erik Sandberg (chair of the board, 17/03/2025), Hans Carl Bøgh-Sørensen (board member, 16/03/2025) and Thomas Hørslev Hedegaard (ceo, 16/04/2026) (+1).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2021–2025 · amounts in DKK thousand

Equity and net profit

DKK 0DKK 10mDKK 20mDKK 30mDKK 40mDKK 50mDKK 60m20212022202320242025
EquityNet profit
Financial figures for Orifarm Manufacturing Hobro A/S
20212022202320242025Change
Revenuenot statednot statednot statednot statednot stated–
Gross profit−160,52562,33958,60457,009−2.7%
Operating profit (EBIT)−16,9878,2826,3856,755+5.8%
Profit before tax16,4206,4583,7024,717+27.4%
Net profit15,0065,0352,8853,792+31.4%
Total assets61,113102,276124,972107,743118,406+9.9%
Equity56,95449,86745,90248,78745,979−5.8%
Liabilities4,15950,74876,83656,23569,874+24.3%
Cash and cash equivalents395140–––
Average number of employees077676260−3.2%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 10mDKK 0DKK 10mDKK 20mDKK 30mDKK 40mDKK 50mDKK 60m20212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Profit for five years in a row

    Net result has been positive in 2021–2025.

    How is this calculated?

    Net result is positive in the five latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

5 financial years
Annual reports for Orifarm Manufacturing Hobro A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202528/05/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202412/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202306/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202207/06/2023The companyPDFXBRL
202101/01/2020 – 31/03/202105/07/2022The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
01020304050607008/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profitDKK 57mNo. 13 of 57
Better than 79% of the companies in the industry
EquityDKK 46mNo. 19 of 59
Better than 69% of the companies in the industry
Number of employees64No. 16 of 59
Better than 74% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bnHere
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 50–199 employees4,467 companies in the comparison
No. 1,530of 4,412
Better than 65%
No. 1,298of 4,466
Better than 71%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 587of 33,588
Better than 98%
No. 1,285of 33,687
Better than 96%
All companies of type A/S18,025 companies in the comparison
No. 2,586of 17,786
Better than 85%
No. 3,772of 18,024
Better than 79%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. Orifarm Manufacturing Hobro A/SDKK 57m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. Orifarm Manufacturing Hobro A/SDKK 3.8m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. Orifarm Manufacturing Hobro A/SDKK 46m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. Orifarm Manufacturing Hobro A/S64
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
Orifarm Manufacturing Hobro A/S

Management

4 active registrations

Executive management

Executive management at Orifarm Manufacturing Hobro A/S
NameRoleAppointed
Mads Fink EriksenCEO16/04/2026

Board of directors

Board of directors at Orifarm Manufacturing Hobro A/S
NameRoleAppointed
Mads Fink EriksenBoard member01/10/2024
Hans Carl Bøgh-SørensenChair of the board17/03/2025
Nicki Lund KristensenBoard member20/10/2025
Founders
ApS Kburs 17 Nr. 6919
Former management (14)
Former management at Orifarm Manufacturing Hobro A/S
NameRoleAppointedResigned
Peter Andreas StakemannDirector01/01/202009/07/2020
Marianne Damgaard-SørensenDirector09/07/202031/03/2021
Ghita AstrupDirector09/07/202031/03/2021
Jacob LucassenDirector31/03/202115/10/2021
Erik SandbergDirector31/03/202115/10/2021
Allan DinesenDirector31/03/202114/10/2021
Jacob LucassenBoard member15/10/202101/10/2024
Erik SandbergChair of the board15/10/202117/03/2025
Allan DinesenCEO15/10/202120/10/2021
Allan DinesenBoard member15/10/202120/10/2021
Hans Carl Bøgh-SørensenBoard member20/10/202116/03/2025
Jacob LucassenCEO20/10/202101/10/2024
Thomas Hørslev HedegaardCEO01/10/202416/04/2026
Thomas Hørslev HedegaardBoard member17/03/202516/04/2026

Signing rule: Selskabet tegnes af den administrerende direktør og bestyrelsesformanden i forening eller af to bestyrelsesmedlemmer i forening.

Address and production units

1 active production units

Apotekerstien 9
9500 Hobro

Mariagerfjord Municipality · Postcode 9500

Production units
Production unitAddressEmployeesP number
Orifarm Manufacturing Hobro A/SApotekerstien 9, 9500 Hobro641025398870

Purpose

Selskabets formål er udvikling og fremstilling af samt handel med lægemidler og hertil beslægtede varer.

The purpose is quoted from the register in Danish.

Changes year by year

52 registered events
20264 changesaccounts 1 · management 3
  • Annual report for 2025 published
  • Mads Fink Eriksen appointed ceo
  • Thomas Hørslev Hedegaard stepped down as board member
  • Thomas Hørslev Hedegaard stepped down as ceo
20256 changesmanagement 5 · accounts 1
  • Nicki Lund Kristensen appointed board member
  • Annual report for 2024 published
  • Hans Carl Bøgh-Sørensen appointed chair of the board
  • Thomas Hørslev Hedegaard appointed board member
  • Erik Sandberg stepped down as chair of the board
  • Hans Carl Bøgh-Sørensen stepped down as board member
20245 changesmanagement 4 · accounts 1
  • Mads Fink Eriksen appointed board member
  • Thomas Hørslev Hedegaard appointed ceo
  • Jacob Lucassen stepped down as ceo
  • Jacob Lucassen stepped down as board member
  • Annual report for 2023 published
20231 changeaccounts 1
  • Annual report for 2022 published
20221 changeaccounts 1
  • Annual report for 2021 published
202124 changesmanagement 16 · name 2 · capital 2 · address 2 · ownership 2
  • Hans Carl Bøgh-Sørensen appointed board member
  • Jacob Lucassen appointed ceo
  • Allan Dinesen stepped down as board member
  • Allan Dinesen stepped down as ceo
  • Name changed from Orifarm Manufacturing Hobro ApS to Orifarm Manufacturing Hobro A/S
  • Share capital changed from 40,100 DKK to 400,000 DKK
  • Allan Dinesen appointed board member
  • Jacob Lucassen appointed board member
  • Erik Sandberg appointed chair of the board
  • Allan Dinesen appointed ceo
  • Erik Sandberg stepped down as director
  • Jacob Lucassen stepped down as director
  • Allan Dinesen stepped down as director
  • Moved to Apotekerstien 9, 9500 Hobro
  • Name changed from Dalmore Invest (Denmark) ApS to Orifarm Manufacturing Hobro ApS
  • Moved to Energivej 15, Lindved, 5260 Odense S
  • Allan Dinesen appointed director
  • Erik Sandberg appointed director
  • Jacob Lucassen appointed director
  • Ghita Astrup stepped down as director
  • Marianne Damgaard-Sørensen stepped down as director
  • ORIFARM GROUP A/S registered as owner (100%)
  • Takeda Pharmaceuticals International AG is no longer registered as owner
  • Share capital changed from 40,000 DKK to 40,100 DKK
202011 changesindustry 1 · address 1 · name 1 · management 4 · ownership 3 · founded 1
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
  • Moved to Delta Park 45, 2665 Vallensbæk Strand
  • Name changed from ApS STM nr. 6418 to Dalmore Invest (Denmark) ApS
  • Ghita Astrup appointed director
  • Marianne Damgaard-Sørensen appointed director
  • Peter Andreas Stakemann stepped down as director
  • Takeda Pharmaceuticals International AG registered as owner (100%)
  • ApS KBURS 17 NR. 6919 is no longer registered as owner
  • Registered as ApS STM nr. 6418
  • Peter Andreas Stakemann appointed director
  • ApS KBURS 17 NR. 6919 registered as owner (100%)

Related companies

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction